Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics to Raise $4.5M Through Direct Offering

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that institutional investors have agreed to around $5.1 million in securities through a direct share offering.

The molecular diagnostics developer plans to use the expected $4.5 million in proceeds from the offering for general corporate purposes.

Rosetta said it has agreed to sell an aggregate of 2.5 million of ordinary shares and warrants to purchase up to about 1.3 million more ordinary shares.

Each unit, consisting of one ordinary share and a warrant to buy one half of an ordinary share, will be sold for a purchase price of $2, the firm said.

The $4.5 million gained from the sale may go to borrowing, working capital, intellectual property protection and enforcement, expenses, investments, mergers and acquisitions or collaborations, research and development, and product development.

The placement, which is being handled by Rodman & Renshaw, is expected to close by January 19.

The firm announced on Wednesday that a joint study with Johns Hopkins University has shown that its miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate blocks.

That news sent Rosetta Genomics' Nasdaq share price soaring, rising as high as $3.20 a share from Tuesday's closing price of $1.85. The stock was trading at $2.06 Thursday morning.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.